Acrivon Therapeutics (NASDAQ:ACRV) Price Target Cut to $19.00 by Analysts at HC Wainwright

Acrivon Therapeutics (NASDAQ:ACRV) had its target price decreased by research analysts at HC Wainwright from $22.00 to $19.00 in a report released on Wednesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s target price indicates a potential upside of 252.50% from the stock’s current price.

Several other analysts have also weighed in on ACRV. KeyCorp assumed coverage on Acrivon Therapeutics in a report on Friday, January 31st. They issued an “overweight” rating for the company. Cantor Fitzgerald started coverage on Acrivon Therapeutics in a report on Friday, January 31st. They issued an “overweight” rating for the company. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Acrivon Therapeutics has an average rating of “Buy” and a consensus price target of $23.17.

Acrivon Therapeutics Stock Performance

Shares of NASDAQ ACRV opened at $5.39 on Wednesday. Acrivon Therapeutics has a 1 year low of $4.69 and a 1 year high of $11.90. The stock’s 50-day simple moving average is $5.54 and its 200-day simple moving average is $6.63. The firm has a market cap of $167.82 million, a price-to-earnings ratio of -2.00 and a beta of 0.85.

Hedge Funds Weigh In On Acrivon Therapeutics

Several institutional investors have recently made changes to their positions in ACRV. China Universal Asset Management Co. Ltd. bought a new stake in shares of Acrivon Therapeutics in the 4th quarter worth approximately $40,000. Wealthedge Investment Advisors LLC acquired a new stake in Acrivon Therapeutics in the 4th quarter valued at approximately $65,000. Corton Capital Inc. bought a new stake in Acrivon Therapeutics during the 4th quarter valued at $73,000. American Century Companies Inc. boosted its position in Acrivon Therapeutics by 14.2% during the 4th quarter. American Century Companies Inc. now owns 17,588 shares of the company’s stock worth $106,000 after acquiring an additional 2,186 shares during the period. Finally, Dimensional Fund Advisors LP grew its stake in shares of Acrivon Therapeutics by 20.2% in the fourth quarter. Dimensional Fund Advisors LP now owns 37,063 shares of the company’s stock worth $223,000 after purchasing an additional 6,239 shares in the last quarter. 71.62% of the stock is owned by institutional investors.

Acrivon Therapeutics Company Profile

Acrivon Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.